The NCCP has published an updated evidence-based National Clinical Guideline. Please note the new guideline (2022) supersedes the recommendations of the previous guideline National Clinical Guideline No. 13 Diagnosis, Staging and Treatment of Patients with Gestational Trophoblastic Disease (2015).
Accessing the guideline
You can download this guideline in PDF format HERE
Information on the National Gestational Trophoblastic Disease Registry Monitoring and Advisory Centre can be found HERE.
- Aim to improve the quality of clinical care,
- Aim to prevent variation in practice,
- Aim to address areas of clinical care with new and emerging evidence,
- They are based on the best current research evidence in conjunction with clinical expertise and patient preferences and values,
- They are developed using a clear evidence-based internationally used methodology.
A Guideline Development Group was responsible for the development of this National Clinical Guideline and included representatives from relevant professional groups and patients. The guideline focuses on the diagnosis, staging and treatment of patients with GTD. It does not include recommendations covering every aspect of diagnosis, staging and treatment. Instead this guideline focuses on areas of clinical practice:
- known to be controversial or uncertain,
- where there is identifiable variation in practice,
- where there is new or emerging evidence,
- where guidelines have potential to have the most impact.
This evidence-based clinical guideline will ensure standardised multidisciplinary care for patients, putting evidence into practice to improve patient outcomes.
Comments should be emailed to email@example.com.
Last updated: 13th May 2022